- Oct 282026
ClearPoint Neuro Reports Third Quarter 2026 Results
Company press release furnished with a Form 8-K filed on Oct 28, 2026.
- Oct 272026
Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
Current report (Form 8-K) filed with the SEC on Oct 27, 2026; the quoted text is from Item 5.02.
- Oct 262026
BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives
Company press release furnished to the SEC with a Form 6-K report on Oct 26, 2026.
- Oct 262026
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Company press release furnished with a Form 8-K filed on Oct 26, 2026.
- Oct 192026
BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group
Company press release furnished to the SEC with a Form 6-K report on Oct 19, 2026.
- Oct 192026
CRISPR Therapeutics reports changes involving its directors or officers (Form 8-K, Item 5.02)
Current report (Form 8-K) filed with the SEC on Oct 19, 2026; the quoted text is from Item 5.02.
- Oct 132026
BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives
Company press release furnished to the SEC with a Form 6-K report on Oct 13, 2026.
- Oct 72026
Longeveron reports changes involving its directors or officers (Form 8-K, Item 5.02)
Current report (Form 8-K) filed with the SEC on Oct 14, 2026; the quoted text is from Item 5.02.
- Oct 52026
NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Company press release furnished with a Form 8-K filed on Oct 5, 2026.
- Oct 52026
Department of Veterans Affairs obligates $31,635 to Myomo
Federal contract record on USAspending.gov, last modified Oct 6, 2026.
- Oct 42026
Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
Current report (Form 8-K) filed with the SEC on Oct 8, 2026; the quoted text is from Item 5.02.
- Oct 12026
Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
Current report (Form 8-K) filed with the SEC on Oct 1, 2026; the quoted text is from Item 5.02.
- Sep 282026
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in Its Transition Toward Commercial Revenue Generation
Company press release furnished with a Form 8-K filed on Oct 1, 2026.
- Sep 282026
Precision Neuroscience reports $250 million of securities sold in a private offering
SEC Form D notice of an offering exempt from registration (Rule 506(b)), filed Sep 28, 2026.
- Sep 252026
Nexalin Technology reports a notice about its stock exchange listing (Form 8-K, Item 3.01)
Current report (Form 8-K) filed with the SEC on Sep 28, 2026; the quoted text is from Item 3.01.
- Sep 222026
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Company press release furnished with a Form 8-K filed on Sep 28, 2026.
- Sep 162026
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Company press release furnished with a Form 8-K filed on Sep 23, 2026.
- Sep 152026
Lifeward reports a shareholder director nomination deadline (Form 8-K, Item 5.08)
Current report (Form 8-K) filed with the SEC on Sep 15, 2026; the quoted text is from Item 5.08.
- Sep 102026
Dexcom Appoints Glenn Boehnlein to Board of Directors
Company press release furnished with a Form 8-K filed on Sep 10, 2026.
- Sep 102026
Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Company press release furnished with a Form 8-K filed on Sep 14, 2026.
- Sep 82026
BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer’s Disease Treated with Deep TMS™
Company press release furnished to the SEC with a Form 6-K report on Sep 8, 2026.
- Sep 82026
electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers
Company press release furnished with a Form 8-K filed on Sep 9, 2026.
- Sep 82026
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Company press release furnished with a Form 8-K filed on Sep 8, 2026.
- Sep 42026
Intellia Therapeutics reports entry into a material definitive agreement (Form 8-K, Item 1.01)
Current report (Form 8-K) filed with the SEC on Sep 4, 2026; the quoted text is from Item 1.01.
- Aug 312026
Lifeward reports changes involving its directors or officers (Form 8-K, Item 5.02)
Current report (Form 8-K) filed with the SEC on Aug 31, 2026; the quoted text is from Item 5.02.